MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above

FDA grants priority review to AstraZeneca's hairy cell leukaemia treatment

AstraZeneca said Friday the US Food and Drug Administration had granted a priority review of the company's hairy cell leukaemia treatment.

The approval of the treatment, Lumoxiti, came after the drug, during a clinical trial, achieved its primary objective of clearing bone marrow of hairy cells and showing a haematologic remission in patients for a duration of more than 180 days.

'Today's FDA approval of Lumoxiti represents a significant milestone for people living with hairy cell leukaemia, a rare blood cancer that can result in serious and life-threatening conditions,' said Dave Fredrickson, Executive Vice-President, Global Head Oncology Business Unit.

'For patients, this approval provides the first FDA-approved medicine for this condition in more than 20 years.'

Story provided by